Unraveling Oxyntomodulin, GLP1's Enigmatic Brother

Overview

Journal J Endocrinol

Specialty Endocrinology

Date 2012 Sep 29

PMID 23019069

Citations 46

Authors

Alessandro Pocai

Affiliations

Soon will be listed here.

Abstract

Oxyntomodulin (OXM) is a peptide secreted from the L cells of the gut following nutrient ingestion. OXM is a dual agonist of the glucagon-like peptide-1 receptor (GLP1R) and the glucagon receptor (GCGR) combining the effects of GLP1 and glucagon to act as a potentially more effective treatment for obesity than GLP1R agonists. Injections of OXM in humans cause a significant reduction in weight and appetite, as well as an increase in energy expenditure. Activation of GCGR is classically associated with an elevation in glucose levels, which would be deleterious in patients with T2DM, but the antidiabetic properties of GLP1R agonism would be expected to counteract this effect. Indeed, OXM administration improved glucose tolerance in diet-induced obese mice. Thus, dual agonists of the GCGR and GLP1R represent a new therapeutic approach for diabetes and obesity with the potential for enhanced weight loss and improvement in glycemic control beyond those of GLP1R agonists.

Citing Articles

Principles and Biomedical Applications of Self-Assembled Peptides: Potential Treatment of Type 2 Diabetes Mellitus.

Mohammad Karim A Pharmaceutics. 2024; 16(11).

PMID: 39598565 PMC: 11597675. DOI: 10.3390/pharmaceutics16111442.

Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy.

Nicze M, Dec A, Borowka M, Krzyzak D, Boldys A, Buldak L Int J Mol Sci. 2024; 25(15).

PMID: 39125772 PMC: 11311839. DOI: 10.3390/ijms25158202.

Class B1 GPCRs: insights into multireceptor pharmacology for the treatment of metabolic disease.

Sangwung P, Ho J, Siddall T, Lin J, Tomas A, Jones B Am J Physiol Endocrinol Metab. 2024; 327(5):E600-E615.

PMID: 38984948 PMC: 11559640. DOI: 10.1152/ajpendo.00371.2023.

Dietary Fibre for the Prevention of Post-Pancreatitis Diabetes Mellitus: A Review of the Literature and Future Research Directions.

Li X, Petrov M Nutrients. 2024; 16(3).

PMID: 38337719 PMC: 10857198. DOI: 10.3390/nu16030435.

Recent Advances in Pharmaceutical Design: Unleashing the Potential of Novel Therapeutics.

Prajapati R, Bhushan B, Singh K, Chopra H, Kumar S, Agrawal M Curr Pharm Biotechnol. 2024; 25(16):2060-2077.

PMID: 38288793 DOI: 10.2174/0113892010275850240102105033.

References

Dakin C, Small C, Batterham R, Neary N, Cohen M, Patterson M . Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology. 2004; 145(6):2687-95. DOI: 10.1210/en.2003-1338. View

Amori R, Lau J, Pittas A . Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007; 298(2):194-206. DOI: 10.1001/jama.298.2.194. View

Baldissera F, Holst J . Glucagon-related peptides in the human gastrointestinal mucosa. Diabetologia. 1984; 26(3):223-8. DOI: 10.1007/BF00252412. View

Bataille D, Gespach C, Tatemoto K, Marie J, Coudray A, Rosselin G . Bioactive enteroglucagon (oxyntomodulin): present knowledge on its chemical structure and its biological activities. Peptides. 1981; 2 Suppl 2:41-4. DOI: 10.1016/0196-9781(81)90008-5. View

Maida A, Lovshin J, Baggio L, Drucker D . The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice. Endocrinology. 2008; 149(11):5670-8. DOI: 10.1210/en.2008-0336. View

DUBRASQUET M, Bataille D, Gespach C . Oxyntomodulin (glucagon-37 or bioactive enteroglucagon): a potent inhibitor of pentagastrin-stimulated acid secretion in rats. Biosci Rep. 1982; 2(6):391-5. DOI: 10.1007/BF01119301. View

Chaudhri O, Parkinson J, Kuo Y, Druce M, Herlihy A, Bell J . Differential hypothalamic neuronal activation following peripheral injection of GLP-1 and oxyntomodulin in mice detected by manganese-enhanced magnetic resonance imaging. Biochem Biophys Res Commun. 2006; 350(2):298-306. DOI: 10.1016/j.bbrc.2006.09.033. View

Amir S . Central glucagon-induced hyperglycemia is mediated by combined activation of the adrenal medulla and sympathetic nerve endings. Physiol Behav. 1986; 37(4):563-6. DOI: 10.1016/0031-9384(86)90286-6. View

Derosa G, Ragonesi P, Carbone A, Fogari E, Bianchi L, Bonaventura A . Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients. Diabetes Technol Ther. 2012; 14(6):475-84. DOI: 10.1089/dia.2011.0278. View

10.

Whitaker G, Lynn F, McIntosh C, Accili E . Regulation of GIP and GLP1 receptor cell surface expression by N-glycosylation and receptor heteromerization. PLoS One. 2012; 7(3):e32675. PMC: 3296735. DOI: 10.1371/journal.pone.0032675. View

11.

Kieffer T, Habener J . The glucagon-like peptides. Endocr Rev. 1999; 20(6):876-913. DOI: 10.1210/edrv.20.6.0385. View

12.

SALTER J, EZRIN C, Laidlaw J, Gornall A . Metabolic effects of glucagon in human subjects. Metabolism. 1960; 9:753-68. View

13.

Meier J, Kemmeries G, Holst J, Nauck M . Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes. 2005; 54(7):2212-8. DOI: 10.2337/diabetes.54.7.2212. View

14.

Barbato A, Russo P, Venezia A, Strazzullo V, Siani A, Cappuccio F . Analysis of Gly40Ser polymorphism of the glucagon receptor (GCGR) gene in different ethnic groups. J Hum Hypertens. 2003; 17(8):577-9. DOI: 10.1038/sj.jhh.1001591. View

15.

Baggio L, Huang Q, Brown T, Drucker D . Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology. 2004; 127(2):546-58. DOI: 10.1053/j.gastro.2004.04.063. View

16.

Parlevliet E, Heijboer A, Schroder-van der Elst J, Havekes L, Romijn J, Pijl H . Oxyntomodulin ameliorates glucose intolerance in mice fed a high-fat diet. Am J Physiol Endocrinol Metab. 2007; 294(1):E142-7. DOI: 10.1152/ajpendo.00576.2007. View

17.

Jorgensen N, Jacobsen S, Dirksen C, Bojsen-Moller K, Naver L, Hvolris L . Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance. Am J Physiol Endocrinol Metab. 2012; 303(1):E122-31. DOI: 10.1152/ajpendo.00073.2012. View

18.

Jorgensen R, Kubale V, Vrecl M, Schwartz T, Elling C . Oxyntomodulin differentially affects glucagon-like peptide-1 receptor beta-arrestin recruitment and signaling through Galpha(s). J Pharmacol Exp Ther. 2007; 322(1):148-54. DOI: 10.1124/jpet.107.120006. View

19.

Blache P, Kervran A, Martinez J, Bataille D . Development of an oxyntomodulin/glicentin C-terminal radioimmunoassay using a "thiol-maleoyl" coupling method for preparing the immunogen. Anal Biochem. 1988; 173(1):151-9. DOI: 10.1016/0003-2697(88)90172-8. View

20.

Du X, Kosinski J, Lao J, Shen X, Petrov A, Chicchi G . Differential effects of oxyntomodulin and GLP-1 on glucose metabolism. Am J Physiol Endocrinol Metab. 2012; 303(2):E265-71. DOI: 10.1152/ajpendo.00142.2012. View